Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Medullary × ponatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 10 Leukemia 4 Neoplasms 3 Leukemia, Myeloid, Chronic-Phase 3 Leukemia, Myeloid, Accelerated Phase 3 Carcinoma, Non-Small-Cell Lung 3 Blast Crisis 3 Leukemia, Myeloid, Acute 2 Gastrointestinal Stromal Tumors 2 Gastrointestinal Neoplasms 2 Thyroid Neoplasms 1 Small Cell Lung Carcinoma 1 Piebaldism 1 Philadelphia Chromosome 1 Neoplasms by Histologic Type 1 Myeloproliferative Disorders 1 Malignant Hepatobiliary Neoplasm 1 Lung Neoplasms 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid 1 Hematologic Diseases 1 Glioblastoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Medullary 1 Carcinoma 1 Bronchiolitis Obliterans Syndrome 1 Breast Neoplasms 1 Bone Marrow Diseases 1 Adenocarcinoma of Lung 1

Interventions

Sorafenib 4 Everolimus 3 vandetanib 2 selpercatinib 2 lutetium Lu 177 dotatate 2 Sunitinib 2 yeast-CEA vaccine 1 tanespimycin 1 sargramostim 1 ponatinib 1 pembrolizumab 1 pazopanib 1 pasireotide 1 nintedanib 1 motesanib diphosphate 1 lenvatinib 1 cabozantinib 1 aldesleukin 1 Vorinostat 1 Thalidomide 1 Temozolomide 1 Pharmacogenomic Testing 1 Octreotide 1 Melphalan 1 Lithium Carbonate 1 Irinotecan 1 Gefitinib 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03838692 2021-10-13

Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

Columbia University

Phase 2 Withdrawn

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡